Abstract
Post stroke depression or PSD is believed to occur in ten to forty percent of all patients who survive stroke. These mood disturbances overlap with primary major depressive disorder in terms of symptom profile, natural history and response to antidepressant medications. Cognitive changes, especially impairments in executive functions, are commonly encountered in PSD. This may be the result of disruption to fronto-thalamo-cortical circuits in PSD. Both functional limitations following stroke and biological mechanisms may play important roles in the pathophysiology of PSD. Antidepressants are clinically effective in managing these mood disturbances and may have an important role in the prophylaxis of depression following stroke. PSD provides a naturalistic model that facilitates the study of the clinical correlates and neurobiological mechanisms that may be relevant in the pathophysiology of vascular depression.
Keywords: stroke, depression, location, executive dysfunction, norepinephrine, serotonin, antidepressants, prophylaxis
Current Neuropharmacology
Title: The Clinical Neuroscience of Post Stroke Depression
Volume: 2 Issue: 4
Author(s): Ebrahim Haroon and Anand Kumar
Affiliation:
Keywords: stroke, depression, location, executive dysfunction, norepinephrine, serotonin, antidepressants, prophylaxis
Abstract: Post stroke depression or PSD is believed to occur in ten to forty percent of all patients who survive stroke. These mood disturbances overlap with primary major depressive disorder in terms of symptom profile, natural history and response to antidepressant medications. Cognitive changes, especially impairments in executive functions, are commonly encountered in PSD. This may be the result of disruption to fronto-thalamo-cortical circuits in PSD. Both functional limitations following stroke and biological mechanisms may play important roles in the pathophysiology of PSD. Antidepressants are clinically effective in managing these mood disturbances and may have an important role in the prophylaxis of depression following stroke. PSD provides a naturalistic model that facilitates the study of the clinical correlates and neurobiological mechanisms that may be relevant in the pathophysiology of vascular depression.
Export Options
About this article
Cite this article as:
Haroon Ebrahim and Kumar Anand, The Clinical Neuroscience of Post Stroke Depression, Current Neuropharmacology 2004; 2 (4) . https://dx.doi.org/10.2174/1570159043359567
DOI https://dx.doi.org/10.2174/1570159043359567 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Cardiovascular Disease Risk Among the Poor and Homeless – What We Know So Far
Current Cardiology Reviews Vascular and Metabolic Actions of the Green Tea Polyphenol Epigallocatechin Gallate
Current Medicinal Chemistry Chest Pain in Children
Current Pediatric Reviews Second-Generation Antipsychotic Agents: A Review of Safety Profiles
Current Psychiatry Reviews Editorial: Liraglutide and Cardiometabolic Effects: More than Just Another Antiobesity Drug?
Current Vascular Pharmacology Phenomics of Vascular Disease: The Systematic Approach to the Combination Therapy
Current Vascular Pharmacology Pulmonary Hypertension and Lung Transplantation
Current Hypertension Reviews Controversies in NSAIDs Use in Cataract Surgery
Current Pharmaceutical Design Immunomodulation and Anti-inflammatory Roles of Polyphenols as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Psychoemotional Background of Temporomandibular Joint Dysfunction and Possible Drug Therapy
Letters in Drug Design & Discovery Genetic Risk Factors in Cerebrovascular Disorders and Cognitive Deterioration
Current Genomics Food and Food Supplements with Hypocholesterolemic Effects
Recent Patents on Food, Nutrition & Agriculture VEGFR2 and VEGF-C Suppresses the Epithelial-Mesenchymal Transition Via YAP in Retinal Pigment Epithelial Cells
Current Molecular Medicine Regenerative Medicine: Does Erythropoietin have a Role?
Current Pharmaceutical Design Editorial (Thematic Issue: Advances in the Diagnosis and Treatment of Polycystic Ovarian Syndrome)
Current Pharmaceutical Design Migraine Attack Treatment : A Tailor-made Suit, Not One Size Fits All
Recent Patents on CNS Drug Discovery (Discontinued) Impaired Cerebral Autoregulation and Vasomotor Reactivity in Sporadic Alzheimer’s Disease
Current Alzheimer Research Atenolol: Differences in Mode of Action Compared with other Antihypertensives.An Opportunity to Identify Features that Influence Outcome?
Current Pharmaceutical Design Statin-induced Vascular Smooth Muscle Cell Apoptosis: A Possible Role in the Prevention of Restenosis?
Current Drug Targets - Cardiovascular & Hematological Disorders Transcranial Doppler Ultrasonography: Current Status
Current Medical Imaging